Breakthrough candidemia during prophylactic or empirical antifungal therapy: antifungal exposure, in vitro activity, and association of early treatment modification with mortality.
文献摘要
Background Breakthrough candidemia (BrC) occurs during systemic antifungal therapy, but its determinants, relationship with in vitro resistance, and optimal management remain unclear. Research design and methods Retrospective matched case-case study at a 900-bed tertiary-care center (2012-2026) including 713 first candidemia episodes (92 BrC, defined as candidemia after ≥72 hours of antifungal exposure; 621 non-BrC). MICs were compared with same-species non-breakthrough isolates. BrC cases were matched 1:1 on age, location and period. The main outcome was 30-day mortality; antifungal therapy modification was evaluated in a 5-day landmark analysis. Results BrC accounted for 12.9% of episodes, arising a median of 8 days into therapy, mostly during echinocandin exposure (73.9%). Of 88 isolates tested against the administered agent, 2 (2.3%) were resistant, 2 (2.3%) non-wild-type and 4 (4.5%) intermediate, and no statistically significant MIC difference was detected across 37 species-antifungal comparisons. Parenteral nutrition and non-C. albicans species were independently associated with BrC. BrC was associated with higher 30-day mortality (aOR 2.00; 95% CI 1.04-3.88). Among day-5 survivors, therapy modification was associated with lower mortality (aOR 0.17; 0.05-0.51; exploratory). Conclusions BrC mainly occurs during echinocandin therapy, rarely involves isolates resistant to the administered agent, and identifies a high-risk group warranting early therapeutic reassessment.